Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AC2993 (Byetta) in T2DM on Metformin and Sulfonylurea
NCT00035984Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- May 2002
- Primary completion
- Aug 2003
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of exenatide in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started May 2002; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00035984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00035984.